Overview
Efficacy of Adding Interleukin-2 to an Optimized Antiretroviral Regimen in HIV Patients in Therapeutic Failure (ANRS123)
Status:
Completed
Completed
Trial end date:
2008-02-01
2008-02-01
Target enrollment:
0
0
Participant gender:
All
All
Summary
Interleukin-2 (IL-2) increases the number of CD4 cells in HIV-1 infected patients with a CD4 cell count over 200/mm3, but its activity in patients with treatment failure and low CD4 cell counts is unknown. This study will test the efficacy and safety of IL-2 with an optimized antiretroviral regimen in patients with a CD4 count below 200/mm3 and a plasma viral load above 10,000 HIV RNA copies/ml.Phase:
Phase 2Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
French National Agency for Research on AIDS and Viral HepatitisCollaborator:
Chiron CorporationTreatments:
Interleukin-2
Criteria
Inclusion Criteria:- Adult patients with proven HIV-1-infection
- Prior or current exposition to at least 1 molecule from each of the 3 antiretroviral
classes (NRTI, NNRTI and PI)
- In a situation of therapeutic failure on an ongoing regimen
Exclusion Criteria:
- Patients included in the Macrolin® expanded French access program